Nefh Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| NEFH Gene | |
|---|---|
| Gene Symbol | NEFH |
| Full Name | Neurofilament Heavy Chain |
| Chromosomal Location | 22q12.2 |
| NCBI Gene ID | 4745 |
| OMIM | 162370 |
| Ensembl ID | ENSG00000100285 |
| UniProt ID | P12036 |
NEFH (Neurofilament Heavy Chain) encodes the heavy subunit of the neurofilament triplet proteins that are essential for axonal structure and function[1]. Neurofilaments are the major intermediate filaments in large myelinated axons, where they provide structural support and regulate axonal caliber, which directly correlates with nerve conduction velocity[2]. NEFH is particularly important in motor and sensory neurons with large axons, and mutations in NEFH have been associated with Charcot-Marie-Tooth disease type 2 (CMT2) and amyotrophic lateral sclerosis (ALS). Additionally, neurofilament light chain (NfL) and heavy chain (NfH) are widely used biomarkers for axonal injury in neurodegenerative diseases[3].
NEFH is one of three neurofilament subunits that polymerize to form intermediate filaments:
NEFH-containing neurofilaments are transported bidirectionally along axons:
The density and spacing of neurofilaments directly influence axonal diameter:
NEFH mutations cause autosomal dominant axonal CMT2:
| Mutation | Effect | Phenotype |
|---|---|---|
| p.K378E | Altered phosphorylation | CMT2 with prominent sensory loss |
| p.S847fs | Frameshift | Early-onset severe neuropathy |
| p.R349C | Reduced assembly | Intermediate CMT phenotype |
Mechanism: Mutations impair neurofilament assembly, transport, or phosphorylation, leading to axonal degeneration[5].
NEFH acts as a disease modifier in ALS:
The study of Nefh Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nixon RA, et al. (1993). Neurofilament proteins. The Neuronal Cytoskeleton. 215-234. ↩︎
Lee MK, et al. (1993). The expression and posttranslational modification of the neurofilament proteins. Journal of Neuroscience Research. 36: 247-258. ↩︎
Petzold A, et al. (2005). Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and clinical outcome. Brain. 128: 2242-2253. ↩︎
Roy S, et al. (2000). Neurofilament transport: dependent on the neuronal activity. Journal of Neuroscience. 20: 6849-6856. ↩︎
Fabrizi GM, et al. (2007). Novel neurofilament light chain (NEFL) and heavy chain (NEFH) mutations cause Charcot-Marie-Tooth disease type 2. Brain. 130: 1704-1714. ↩︎
Yabe JT, et al. (1999). Identification of the intermediate filament-associated protein gyronemin as a binding partner for neurofilament proteins. Cell Motility and the Cytoskeleton. 44: 32-46. ↩︎